Heterodimeric antibodies that bind CD3 and tumor antigens

Patent metadata

Field	Value
Publication number	US-10889653-B2
Application number	US-201514952714-A
Country	US
Kind code	B2
Filing date	Nov 25, 2015
Priority date	Nov 26, 2014
Publication date	Jan 12, 2021
Grant date	Jan 12, 2021

Abstract

The present invention is directed to novel heterodimeric antibodies.

First claim

What is claimed is:

1. A heterodimeric antibody comprising:
a) a first monomer comprising:
i) a first heavy chain comprising:
1) a first variable heavy domain;
2) a first constant heavy chain comprising a first Fc domain;
3) a scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain; wherein said scFv is covalently attached to the C-terminus of said Fc domain using a domain linker;

b) a second monomer comprising a second heavy chain comprising a second variable heavy domain and a second constant heavy chain comprising a second Fc domain; and
c) a common light chain comprising a variable light domain and a constant light domain;
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S364K/E357Q:L368D/K370S; L368D/K370S:S364K; L368E/K370S:S364K; T411E/K360E/Q362E:D401K; L368D/K370S:S364K/E357L and K370S:S364K/E357Q,
wherein said first variable heavy domain and said variable light domain bind a first target tumor antigen (TTA), said second variable heavy domain and said variable light domain bind said first TTA, and said scFv binds human CD3, and
wherein said heterodimeric antibody is a trivalent antibody.

2. A heterodimeric antibody comprising:
a) a first monomer comprising:
i) a first heavy chain comprising:
1) a first variable heavy domain;
2) a first constant heavy chain comprising a first CH1 domain and a first Fc domain;
3) a scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain; wherein said scFv is covalently attached between the C-terminus of said CH1 domain and the N-terminus of said first Fc domain using domain linkers;

b) a second monomer comprising a VH-CH1-hinge-CH2-CH3 monomer, wherein VH is a second variable heavy chain and CH2-CH3 is a second IgG Fc domain; and
c) a common light chain comprising a variable light domain and a constant light domain;
wherein said first and said second Fc domain have a set of amino acid substitutions selected from the group consisting of S364K/E357Q:L368D/K370S; L368D/K370S:S364K; L368E/K370S:S364K; T411E/K360E/Q362E:D401K; L368D/K370S:S364K/E357L and K370S:S364K/E357Q,
wherein said first variable heavy domain and said variable light domain bind a first TTA, said second variable heavy domain and said variable light domain bind said TTA, and said scFv binds human CD3, and
wherein said heterodimeric antibody is a trivalent antibody.

3. A heterodimeric antibody comprising:
a) a first monomer comprising:
i) a first variable heavy domain;
ii) a first constant heavy domain comprising a first CH1 domain and a first Fc domain; and
iii) a first variable light domain, wherein said first variable light domain is covalently attached between the C-terminus of the first CH1 domain of said first constant heavy domain and the N-terminus of said first Fc domain using domain linkers;

b) a second monomer comprising:
i) a second variable heavy domain;
ii) a second constant heavy domain comprising a second CH1 and a second Fc domain; and
iii) a third variable heavy domain, wherein said third variable heavy domain is covalently attached between the C-terminus of the second CH1 domain of said second constant heavy domain and the N-terminus of said second Fc domain using domain linkers;

c) a common light chain comprising a second variable light domain and a constant light domain;
wherein said first and said second Fc domains have a set of amino acid substitutions selected from the group consisting of S364K/E357Q:L368D/K370S; L368D/K370S:S364K; L368E/K370S:S364K; T411E/K360E/Q362E:D401K; L368D/K370S:S364K/E357L and K370S:S364K/E357Q,
and wherein said first variable heavy domain and said second variable light domain bind a first TTA, said second variable heavy domain and said second variable light domain bind said TTA, and said first variable light domain and said third variable heavy domain binds human CD3.

4. A heterodimeric antibody comprising:
a) a first monomer comprising:
i) a first heavy chain comprising:
1) a first variable heavy domain;
2) a first constant heavy chain comprising a first CH1 domain and a first Fc domain;
3) a scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain; wherein said scFv is covalently attached between the C-terminus of said CH1 domain and the N-terminus of said first Fc domain using domain linkers;

b) a second monomer comprising a second Fc domain; and
c) a light chain comprising a variable light domain and a constant light domain;
wherein said first and said second Fc domain have a set of amino acid substitutions selected from the group consisting of S364K/E357Q:L368D/K370S; L368D/K370S:S364K; L368E/K370S:S364K; T411E/K360E/Q362E:D401K; L368D/K370S:S364K/E357L and K370S:S364K/E357Q,
wherein said first variable heavy domain and said variable light domain bind a first antigen, said scFv binds a second antigen, and
wherein said heterodimeric antibody is a bivalent antibody.

Assignees

• Xencor Inc

Inventors

• Bernett Matthew J
• Moore Gregory
• Desjarlais John
• Chu Seung
• Rashid Rumana
• Muchhal Umesh
• Lee Sung-Hyung

Classifications

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/31

  multispecific · CPC title

• A61K2039/505

  comprising antibodies · CPC title